In the present animal model, the increased percentages of Tregs are noted in systemic (splenocytes) and local (TACs) immunities during tumor progression (Fig. 4), but the alterations of CD8+ T cells are different (Figs. 2D2 and 3B2). This evidence concerns the gene CD8A and neoplasm.